181 related articles for article (PubMed ID: 35273656)
1. Serum Autoantibodies against LRDD, STC1, and FOXA1 as Biomarkers in the Detection of Ovarian Cancer.
Duan Y; Cui C; Qiu C; Sun G; Wang X; Wang P; Ye H; Dai L; Shi J
Dis Markers; 2022; 2022():6657820. PubMed ID: 35273656
[TBL] [Abstract][Full Text] [Related]
2. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
[TBL] [Abstract][Full Text] [Related]
3. Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer.
Qiu C; Duan Y; Wang B; Shi J; Wang P; Ye H; Dai L; Zhang J; Wang X
Front Immunol; 2021; 12():698312. PubMed ID: 34489945
[TBL] [Abstract][Full Text] [Related]
4. Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer.
Ma Y; Wang X; Qiu C; Qin J; Wang K; Sun G; Jiang D; Li J; Wang L; Shi J; Wang P; Ye H; Dai L; Jiang BH; Zhang J
Cancer Sci; 2021 Feb; 112(2):537-549. PubMed ID: 33185955
[TBL] [Abstract][Full Text] [Related]
5. Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer.
Cheng Y; Li Q; Sun G; Li T; Zou Y; Ye H; Wang K; Shi J; Wang P
Sci Rep; 2024 Apr; 14(1):9757. PubMed ID: 38684875
[TBL] [Abstract][Full Text] [Related]
6. Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer.
Sun H; Shi JX; Zhang HF; Xing MT; Li P; Dai LP; Luo CL; Wang X; Wang P; Ye H; Li LX; Zhang JY
Tumour Biol; 2017 Jun; 39(6):1010428317699132. PubMed ID: 28618923
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
[TBL] [Abstract][Full Text] [Related]
8. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
[No Abstract] [Full Text] [Related]
9. A combined biomarker panel shows improved sensitivity and specificity for detection of ovarian cancer.
Mao L; Tang Y; Deng MJ; Huang CT; Lan D; Nong WZ; Li L; Wang Q
J Clin Lab Anal; 2022 Feb; 36(2):e24232. PubMed ID: 34995016
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
[TBL] [Abstract][Full Text] [Related]
11. Comparison of candidate serologic markers for type I and type II ovarian cancer.
Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
[TBL] [Abstract][Full Text] [Related]
13. Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis.
Shi JX; Qin JJ; Ye H; Wang P; Wang KJ; Zhang JY
Expert Rev Mol Diagn; 2015 Jun; 15(6):829-52. PubMed ID: 25959246
[TBL] [Abstract][Full Text] [Related]
14. Changes in tumor markers, coagulation function and serum VEGF in patients with ovarian cancer and benign ovarian disease.
Wang J; Zhu M; Zhou X; Wang T; Zhang J
J BUON; 2020; 25(5):2287-2292. PubMed ID: 33277847
[TBL] [Abstract][Full Text] [Related]
15. Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.
Karabudak AA; Hafner J; Shetty V; Chen S; Secord AA; Morse MA; Philip R
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1757-70. PubMed ID: 23999876
[TBL] [Abstract][Full Text] [Related]
16. Development of a panel of serum IgG and IgA autoantibodies for early diagnosis of colon cancer.
Chen M; Lin X; Zhang L; Yu L; Wu Q; Zhang S; Xue F; Huang Y
Int J Med Sci; 2020; 17(17):2744-2750. PubMed ID: 33162802
[No Abstract] [Full Text] [Related]
17. BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer.
Pilyugin M; Ratajska M; Stukan M; Concin N; Zeillinger R; Irminger-Finger I
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34201956
[TBL] [Abstract][Full Text] [Related]
18. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.
Høgdall EV; Høgdall CK; Blaakaer J; Heegaard NH; Glud E; Christensen L; Bock JE; Nørgaard-Pedersen B; Wiik A; Kjaer SK
APMIS; 2002 Aug; 110(7-8):545-53. PubMed ID: 12390412
[TBL] [Abstract][Full Text] [Related]
19. Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma.
Xu YW; Chen H; Guo HP; Yang SH; Luo YH; Liu CT; Huang XY; Tang XM; Hong CQ; Li EM; Xu LY; Peng YH
Gastric Cancer; 2019 May; 22(3):546-557. PubMed ID: 30426295
[TBL] [Abstract][Full Text] [Related]
20. Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.
Yu-Rice Y; Edassery SL; Urban N; Hellstrom I; Hellstrom KE; Deng Y; Li Y; Luborsky JL
Reproduction; 2017 Mar; 153(3):277-284. PubMed ID: 27965399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
